Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on the Pharmacokinetics of LTG-321 in Healthy Participants
NCT07915947Phase 1Not yet recruiting
- Sponsor
- Latigo Biotherapeutics
- Start
- Dec 2026
- Primary completion
- Dec 2026
01
Overview
Phase 1, randomised, open-label trial of LTG-321 in pain (2 arms), sponsored by Latigo Biotherapeutics. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Measurable Concentration at 240 hours, Maximum Observed Plasma Concentration at 240 hours and 1 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
LTG-321
03
Conditions
pain
Beyond the preview
Go deeper on NCT07915947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07915947.